{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:02:44Z","timestamp":1793898164863,"version":"4.8.0"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41401-024-01472-9","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:10:48Z","timestamp":1738757448000},"page":"1495-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery"],"prefix":"10.1038","volume":"46","author":[{"given":"Si-yuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-hua","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"1472_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","volume":"16","author":"L Cristino","year":"2020","unstructured":"Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16:9\u201329.","journal-title":"Nat Rev Neurol"},{"key":"1472_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/bja\/76.1.167","volume":"76","author":"ME West","year":"1996","unstructured":"West ME, Homi J. Cannabis as a medicine. Br J Anaesth. 1996;76:167.","journal-title":"Br J Anaesth"},{"key":"1472_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","volume":"28","author":"AW Zuardi","year":"2006","unstructured":"Zuardi AW. History of cannabis as a medicine: a review. Braz J Psychiatry. 2006;28:153\u20137.","journal-title":"Braz J Psychiatry"},{"key":"1472_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0022-3565(25)13256-4","volume":"247","author":"PJ Little","year":"1988","unstructured":"Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988;247:1046\u201351.","journal-title":"J Pharmacol Exp Ther"},{"key":"1472_CR5","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3390\/molecules26092774","volume":"26","author":"MM Radwan","year":"2021","unstructured":"Radwan MM, Chandra S, Gul S, ElSohly MA. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules. 2021;26:2774.","journal-title":"Molecules."},{"key":"1472_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1021\/ja01861a011","volume":"62","author":"R Adams","year":"1940","unstructured":"Adams R, Hunt M, Clark JH. Structure of cannabidiol. III. Reduction and cleavage. J Am Chem Soc. 1940;62:735\u20137.","journal-title":"Reduction and cleavage. J Am Chem Soc"},{"key":"1472_CR7","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","volume":"19","author":"R Mechoulam","year":"1963","unstructured":"Mechoulam R, Shvo Y, Hashish I. The structure of cannabidiol. Tetrahedron. 1963;19:2073\u20138.","journal-title":"Tetrahedron."},{"key":"1472_CR8","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","volume":"86","author":"Y Gaoni","year":"1964","unstructured":"Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646\u20137.","journal-title":"J Am Chem Soc"},{"key":"1472_CR9","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","volume":"9","author":"JA Crippa","year":"2018","unstructured":"Crippa JA, Guimar\u00e3es FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. 2018;9:2009.","journal-title":"Front Immunol"},{"key":"1472_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57369-0_1","volume":"1264","author":"EM Rock","year":"2021","unstructured":"Rock EM, Parker LA. Constituents of Cannabis sativa. Adv Exp Med Biol. 2021;1264:1\u201313.","journal-title":"Adv Exp Med Biol"},{"key":"1472_CR11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tem.2022.08.003","volume":"33","author":"E Ghasemi-Gojani","year":"2022","unstructured":"Ghasemi-Gojani E, Kovalchuk I, Kovalchuk O. Cannabinoids and terpenes for diabetes mellitus and its complications: from mechanisms to new therapies. Trends Endocrinol Metab. 2022;33:828\u201349.","journal-title":"Trends Endocrinol Metab"},{"key":"1472_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946\u20139.","journal-title":"Science."},{"key":"1472_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","volume":"50","author":"R Mechoulam","year":"1995","unstructured":"Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83\u201390.","journal-title":"Biochem Pharmacol"},{"key":"1472_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","volume":"34","author":"WA Devane","year":"1988","unstructured":"Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605\u201313.","journal-title":"Mol Pharmacol"},{"key":"1472_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61\u20135.","journal-title":"Nature."},{"key":"1472_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1083\/jcb.200305129","volume":"163","author":"T Bisogno","year":"2003","unstructured":"Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463\u20138.","journal-title":"J Cell Biol"},{"key":"1472_CR17","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1074\/jbc.M306642200","volume":"279","author":"Y Okamoto","year":"2004","unstructured":"Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279:5298\u2013305.","journal-title":"J Biol Chem"},{"key":"1472_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/384083a0","volume":"384","author":"BF Cravatt","year":"1996","unstructured":"Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83\u20137.","journal-title":"Nature."},{"key":"1472_CR19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/cbdv.200790155","volume":"4","author":"Y Okamoto","year":"2007","unstructured":"Okamoto Y, Wang J, Morishita J, Ueda N. Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers. 2007;4:1842\u201357.","journal-title":"Chem Biodivers"},{"key":"1472_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1523\/JNEUROSCI.17-04-01226.1997","volume":"17","author":"H Cadas","year":"1997","unstructured":"Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci. 1997;17:1226\u201342.","journal-title":"J Neurosci"},{"key":"1472_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prostaglandins.2008.12.002","volume":"89","author":"J Wang","year":"2009","unstructured":"Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. 2009;89:112\u20139.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1472_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"H-C Lu","year":"2016","unstructured":"Lu H-C, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516\u201325.","journal-title":"Biol Psychiatry"},{"key":"1472_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/bph.12411","volume":"171","author":"N Murataeva","year":"2014","unstructured":"Murataeva N, Straiker A, Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol. 2014;171:1379\u201391.","journal-title":"Br J Pharmacol"},{"key":"1472_CR24","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","volume":"14","author":"JL Blankman","year":"2007","unstructured":"Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007;14:1347\u201356.","journal-title":"Chem Biol"},{"key":"1472_CR25","first-page":"607","volume":"6","author":"H-C Lu","year":"2021","unstructured":"Lu H-C, Mackie K. Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6:607\u201315.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"1472_CR26","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1210\/jc.2005-2679","volume":"91","author":"I Matias","year":"2006","unstructured":"Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91:3171\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"1472_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/sj.bjp.0704767","volume":"136","author":"TC Kirkham","year":"2002","unstructured":"Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550\u20137.","journal-title":"Br J Pharmacol"},{"key":"1472_CR28","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.1523\/JNEUROSCI.2648-09.2010","volume":"30","author":"F Massa","year":"2010","unstructured":"Massa F, Mancini G, Schmidt H, Steindel F, Mackie K, Angioni C, et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci. 2010;30:6273\u201381.","journal-title":"J Neurosci"},{"key":"1472_CR29","first-page":"1363","volume":"48","author":"N Mattelaer","year":"2024","unstructured":"Mattelaer N, Van der Schueren B, Van Oudenhove L, Weltens N, Vangoitsenhoven R. The circulating and central endocannabinoid system in obesity and weight loss. Int J Obes. 2024;48:1363\u201382.","journal-title":"Int J Obes"},{"key":"1472_CR30","doi-asserted-by":"publisher","first-page":"5519396","DOI":"10.1155\/2024\/5519396","volume":"2024","author":"MF Urmeneta-Ort\u00edz","year":"2024","unstructured":"Urmeneta-Ort\u00edz MF, Tejeda-Mart\u00ednez AR, Gonz\u00e1lez-Reynoso O, Flores-Soto ME. Potential neuroprotective effect of the endocannabinoid system on Parkinson\u2019s disease. Parkinsons Dis. 2024;2024:5519396.","journal-title":"Parkinsons Dis"},{"key":"1472_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/brainsci13020325","volume":"13","author":"A Hasbi","year":"2023","unstructured":"Hasbi A, Madras BK, George SR. Endocannabinoid system and exogenous cannabinoids in depression and anxiety: a review. Brain Sci. 2023;13:325.","journal-title":"Brain Sci"},{"key":"1472_CR32","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1097\/j.pain.0000000000002268","volume":"162","author":"DP Finn","year":"2021","unstructured":"Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain. 2021;162:S5\u201325.","journal-title":"Pain."},{"key":"1472_CR33","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.3390\/ijms21124448","volume":"21","author":"O Almogi-Hazan","year":"2020","unstructured":"Almogi-Hazan O, Or R. Cannabis, the endocannabinoid system and immunity-the journey from the bedside to the bench and back. Int J Mol Sci. 2020;21:4448.","journal-title":"Int J Mol Sci"},{"key":"1472_CR34","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.3390\/ijms24031989","volume":"24","author":"D Matei","year":"2023","unstructured":"Matei D, Trofin D, Iordan DA, Onu I, Condurache I, Ionite C, et al. The endocannabinoid system and physical exercise. Int J Mol Sci. 2023;24:1989.","journal-title":"Int J Mol Sci"},{"key":"1472_CR35","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","volume":"11","author":"G Marsicano","year":"1999","unstructured":"Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci. 1999;11:4213\u201325.","journal-title":"Eur J Neurosci"},{"key":"1472_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13724-x","volume":"12","author":"S Chou","year":"2022","unstructured":"Chou S, Ranganath T, Fish KN, Lewis DA, Sweet RA. Cell type specific cannabinoid CB1 receptor distribution across the human and non-human primate cortex. Sci Rep. 2022;12:9605.","journal-title":"Sci Rep"},{"key":"1472_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"S Gali\u00e8gue","year":"1995","unstructured":"Gali\u00e8gue S, Mary S, Marchand J, Dussossoy D, Carri\u00e8re D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54\u201361.","journal-title":"Eur J Biochem"},{"key":"1472_CR38","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.4049\/jimmunol.1102195","volume":"187","author":"S Basu","year":"2011","unstructured":"Basu S, Ray A, Dittel BN. Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol. 2011;187:5720\u201332.","journal-title":"J Immunol"},{"key":"1472_CR39","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/adb.12367","volume":"22","author":"HY Zhang","year":"2017","unstructured":"Zhang HY, Gao M, Shen H, Bi GH, Yang HJ, Liu QR, et al. Expression of functional cannabinoid CB2 receptor in VTA dopamine neurons in rats. Addict Biol. 2017;22:752\u201365.","journal-title":"Addict Biol"},{"key":"1472_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12974-018-1174-9","volume":"15","author":"A L\u00f3pez","year":"2018","unstructured":"L\u00f3pez A, Aparicio N, Pazos MR, Grande MT, Barreda-Manso MA, Benito-Cuesta I, et al. Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer\u2019s disease. J Neuroinflamm. 2018;15:158.","journal-title":"J Neuroinflamm"},{"key":"1472_CR41","doi-asserted-by":"crossref","unstructured":"Marcu JP, Schechter JB. Molecular pharmacology of CB1 and CB2 cannabinoid receptors. 2016:713\u201321.","DOI":"10.1016\/B978-0-12-800213-1.00066-3"},{"key":"1472_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1146\/annurev.pa.35.040195.003135","volume":"35","author":"AC Howlett","year":"1995","unstructured":"Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol. 1995;35:607\u201334.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1472_CR43","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/sj.bjp.0701101","volume":"120","author":"YP Maneuf","year":"1997","unstructured":"Maneuf YP, Brotchie JM. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol. 1997;120:1397\u20138.","journal-title":"Br J Pharmacol"},{"key":"1472_CR44","doi-asserted-by":"publisher","unstructured":"Thomas A, Lobingier B, Schultz C, Laguerre A. Cannabinoid receptor signaling is dependent on sub-cellular location. 2024 [cited 2024 Oct 14]. Available from: https:\/\/doi.org\/10.1101\/2024.03.21.586146.","DOI":"10.1101\/2024.03.21.586146"},{"key":"1472_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1021\/acsptsci.9b00049","volume":"2","author":"Y Saroz","year":"2019","unstructured":"Saroz Y, Kho DT, Glass M, Graham ES, Grimsey NL. Cannabinoid Receptor 2 (CB2) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes. ACS Pharmacol Transl Sci. 2019;2:414\u201328.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1472_CR46","doi-asserted-by":"publisher","first-page":"19144","DOI":"10.1073\/pnas.0509588102","volume":"102","author":"JE Lauckner","year":"2005","unstructured":"Lauckner JE, Hille B, Mackie K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq\/11 G proteins. Proc Natl Acad Sci USA. 2005;102:19144\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1472_CR47","doi-asserted-by":"publisher","first-page":"e2306311","DOI":"10.1002\/advs.202306311","volume":"11","author":"T Wang","year":"2024","unstructured":"Wang T, Tang W, Zhao Z, Zhao R, Lv Z, Guo X, et al. Fenofibrate recognition and Gq protein coupling mechanisms of the human cannabinoid receptor CB1. Adv Sci. 2024;11:e2306311.","journal-title":"Adv Sci"},{"key":"1472_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05032-z","volume":"13","author":"A S\u00e1nchez-de La Torre","year":"2022","unstructured":"S\u00e1nchez-de La Torre A, Aguado T, Huerga-G\u00f3mez A, Santamar\u00eda S, Gentile A, Chara JC, et al. Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice. Cell Death Dis. 2022;13:585.","journal-title":"Cell Death Dis"},{"key":"1472_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.271.5247.363","volume":"271","author":"SS Ferguson","year":"1996","unstructured":"Ferguson SS, Downey WE, Colapietro AM, Barak LS, M\u00e9nard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 1996;271:363\u20136.","journal-title":"Science."},{"key":"1472_CR50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/mol.111.074013","volume":"81","author":"BK Atwood","year":"2012","unstructured":"Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol. 2012;81:250\u201363.","journal-title":"Mol Pharmacol"},{"key":"1472_CR51","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1523\/JNEUROSCI.19-10-03773.1999","volume":"19","author":"W Jin","year":"1999","unstructured":"Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, et al. Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci. 1999;19:3773\u201380.","journal-title":"J Neurosci"},{"key":"1472_CR52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/FJC.0000000000000482","volume":"70","author":"P-Y Jean-Charles","year":"2017","unstructured":"Jean-Charles P-Y, Kaur S, Shenoy SK. G protein-coupled receptor signaling through \u03b2-arrestin-dependent mechanisms. J Cardiovasc Pharmacol. 2017;70:142\u201358.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1472_CR53","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1091\/mbc.e17-03-0198","volume":"28","author":"C Nogueras-Ortiz","year":"2017","unstructured":"Nogueras-Ortiz C, Roman-Vendrell C, Mateo-Semidey GE, Liao YH, Kendall DA, Yudowski GA. Retromer stops beta-arrestin 1-mediated signaling from internalized cannabinoid 2 receptors. Mol Biol Cell. 2017;28:3554\u201361.","journal-title":"Mol Biol Cell"},{"key":"1472_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5589","volume":"5","author":"J Flores-Otero","year":"2014","unstructured":"Flores-Otero J, Ahn KH, Delgado-Peraza F, Mackie K, Kendall DA, Yudowski GA. Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1. Nat Commun. 2014;5:4589.","journal-title":"Nat Commun"},{"key":"1472_CR55","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1124\/mol.115.103176","volume":"89","author":"F Delgado-Peraza","year":"2016","unstructured":"Delgado-Peraza F, Ahn KH, Nogueras-Ortiz C, Mungrue IN, Mackie K, Kendall DA, et al. Mechanisms of biased \u03b2-arrestin-mediated signaling downstream from the cannabinoid 1 receptor. Mol Pharmacol. 2016;89:618\u201329.","journal-title":"Mol Pharmacol"},{"key":"1472_CR56","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0301-0082(02)00009-6","volume":"66","author":"MJ Millan","year":"2002","unstructured":"Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355\u2013474.","journal-title":"Prog Neurobiol"},{"key":"1472_CR57","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3390\/ph3082661","volume":"3","author":"E Palazzo","year":"2010","unstructured":"Palazzo E, Luongo L, de Novellis V, Rossi F, Maione S. The role of cannabinoid receptors in the descending modulation of pain. Pharmaceuticals. 2010;3:2661\u201373.","journal-title":"Pharmaceuticals."},{"key":"1472_CR58","doi-asserted-by":"crossref","unstructured":"Busquets Garcia A, Soria-Gomez E, Bellocchio L, Marsicano G. Cannabinoid receptor type-1: breaking the dogmas. F1000Research, 2016, 5.","DOI":"10.12688\/f1000research.8245.1"},{"key":"1472_CR59","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","volume":"73","author":"C Turcotte","year":"2016","unstructured":"Turcotte C, Blanchet M-R, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73:4449\u201370.","journal-title":"Cell Mol Life Sci"},{"key":"1472_CR60","doi-asserted-by":"publisher","first-page":"105226","DOI":"10.1016\/j.neubiorev.2023.105226","volume":"150","author":"W Grabon","year":"2023","unstructured":"Grabon W, Rheims S, Smith J, Bodennec J, Belmeguenai A, Bezin L. CB2 receptor in the CNS: from immune and neuronal modulation to behavior. Neurosci Biobehav Rev. 2023;150:105226.","journal-title":"Neurosci Biobehav Rev"},{"key":"1472_CR61","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1111\/epi.13930","volume":"58","author":"S Rowley","year":"2017","unstructured":"Rowley S, Sun X, Lima IV, Tavenier A, de Oliveira ACP, Dey SK. et al. Cannabinoid receptor 1\/2 double-knockout mice develop epilepsy. Epilepsia. 2017;58:e162\u20136.","journal-title":"Epilepsia."},{"key":"1472_CR62","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.autrev.2016.02.008","volume":"15","author":"V Katchan","year":"2016","unstructured":"Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: a systematic review. Autoimmun Rev. 2016;15:513\u201328.","journal-title":"Autoimmun Rev"},{"key":"1472_CR63","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s43440-021-00270-y","volume":"73","author":"M Bryk","year":"2021","unstructured":"Bryk M, Starowicz K. Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review. Pharmacol Rep. 2021;73:681\u201399.","journal-title":"Pharmacol Rep"},{"key":"1472_CR64","doi-asserted-by":"publisher","first-page":"828895","DOI":"10.3389\/fpsyt.2022.828895","volume":"13","author":"H Ishiguro","year":"2022","unstructured":"Ishiguro H, Kibret BG, Horiuchi Y, Onaivi ES. Potential role of cannabinoid type 2 receptors in neuropsychiatric and neurodegenerative disorders. Front Psychiatry. 2022;13:828895.","journal-title":"Front Psychiatry"},{"key":"1472_CR65","doi-asserted-by":"publisher","first-page":"841766","DOI":"10.3389\/fphar.2022.841766","volume":"13","author":"S Ruiz de Mart\u00edn Esteban","year":"2022","unstructured":"Ruiz de Mart\u00edn Esteban S, Benito-Cuesta I, Terradillos I, Mart\u00ednez-Relimpio AM, Arnanz MA, Ruiz-P\u00e9rez G, et al. Cannabinoid CB2 Receptors modulate microglia function and amyloid dynamics in a mouse model of Alzheimer\u2019s disease. Front Pharmacol. 2022;13:841766.","journal-title":"Front Pharmacol"},{"key":"1472_CR66","doi-asserted-by":"publisher","first-page":"109745","DOI":"10.1016\/j.pnpbp.2019.109745","volume":"96","author":"QW Han","year":"2020","unstructured":"Han QW, Yuan YH, Chen NH. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109745.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1472_CR67","doi-asserted-by":"publisher","first-page":"14136","DOI":"10.1073\/pnas.96.24.14136","volume":"96","author":"Z J\u00e1rai","year":"1999","unstructured":"J\u00e1rai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 1999;96:14136\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1472_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-11-44","volume":"11","author":"D McHugh","year":"2010","unstructured":"McHugh D, Hu SSJ, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010;11:44.","journal-title":"BMC Neurosci"},{"key":"1472_CR69","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1006\/geno.1997.4752","volume":"42","author":"I Gantz","year":"1997","unstructured":"Gantz I, Muraoka A, Yang YK, Samuelson LC, Zimmerman EM, Cook H, et al. Cloning and chromosomal localization of a gene (GPR18) encoding a novel seven transmembrane receptor highly expressed in spleen and testis. Genomics. 1997;42:462\u20136.","journal-title":"Genomics."},{"key":"1472_CR70","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1111\/j.1476-5381.2011.01497.x","volume":"165","author":"D McHugh","year":"2012","unstructured":"McHugh D, Page J, Dunn E, Bradshaw HB. \u0394(9)-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012;165:2414\u201324.","journal-title":"Br J Pharmacol"},{"key":"1472_CR71","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1755-148X.2010.00781.x","volume":"24","author":"Y Qin","year":"2011","unstructured":"Qin Y, Verdegaal EME, Siderius M, Bebelman JP, Smit MJ, Leurs R, et al. Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res. 2011;24:207\u201318.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1472_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/srep32255","volume":"6","author":"C Flegel","year":"2016","unstructured":"Flegel C, Vogel F, Hofreuter A, Wojcik S, Schoeder C, Kie\u0107-Kononowicz K, et al. Characterization of non-olfactory GPCRs in human sperm with a focus on GPR18. Sci Rep. 2016;6:32255.","journal-title":"Sci Rep"},{"key":"1472_CR73","doi-asserted-by":"publisher","first-page":"106832","DOI":"10.1016\/j.phrs.2023.106832","volume":"195","author":"M Zhao","year":"2023","unstructured":"Zhao M, Zheng Z, Yin Z, Zhang J, Qin J, Wan J, et al. Resolvin D2 and its receptor GPR18 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target. Pharmacol Res. 2023;195:106832.","journal-title":"Pharmacol Res"},{"key":"1472_CR74","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/molecules29061258","volume":"29","author":"E Honkisz-Orzechowska","year":"2024","unstructured":"Honkisz-Orzechowska E, \u0141a\u017cewska D, Baran G, Kie\u0107-Kononowicz K. Uncovering the power of GPR18 signalling: how RvD2 and other ligands could have the potential to modulate and resolve inflammation in various health disorders. Molecules. 2024;29:1258.","journal-title":"Molecules."},{"key":"1472_CR75","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1515\/jbcpp-2015-0080","volume":"27","author":"H Yang","year":"2016","unstructured":"Yang H, Zhou J, Lehmann C. GPR55\u2014a putative \u201ctype 3\u201d cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016;27:297\u2013302.","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"1472_CR76","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.0711278105","volume":"105","author":"JE Lauckner","year":"2008","unstructured":"Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA. 2008;105:2699\u2013704.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1472_CR77","doi-asserted-by":"crossref","unstructured":"Xia R, Yuan Q, Wang N, Hou L, Abe J, Song J, et al. Structural insight into GPR55 ligand recognition and G-protein coupling. Cell Res. 2024: 1-4.","DOI":"10.1038\/s41422-024-01044-w"},{"key":"1472_CR78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pain.2008.04.006","volume":"139","author":"PC Staton","year":"2008","unstructured":"Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 2008;139:225\u201336.","journal-title":"Pain."},{"key":"1472_CR79","doi-asserted-by":"crossref","unstructured":"Andradas C, Caffarel MM, P\u00e9rez-G\u00f3mez E, Guzm\u00e1n M, S\u00e1nchez C. The role of GPR55 in cancer. endoCANNABINOIDS: actions at non-CB1\/CB2 cannabinoid receptors. 2013:115\u201333.","DOI":"10.1007\/978-1-4614-4669-9_5"},{"key":"1472_CR80","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s44161-022-00155-0","volume":"1","author":"R Guillamat-Prats","year":"2022","unstructured":"Guillamat-Prats R, Hering D, Derle A, Rami M, H\u00e4rdtner C, Santovito D, et al. GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation. Nat Cardiovasc Res. 2022;1:1056\u201371.","journal-title":"Nat Cardiovasc Res"},{"key":"1472_CR81","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","volume":"3","author":"HA Overton","year":"2006","unstructured":"Overton HA, Babbs AJ, Doel SM, Fyfe MCT, Gardner LS, Griffin G, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006;3:167\u201375.","journal-title":"Cell Metab"},{"key":"1472_CR82","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1038\/sj.bjp.0707529","volume":"153","author":"HA Overton","year":"2008","unstructured":"Overton HA, Fyfe MCT, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153:S76\u201381.","journal-title":"Br J Pharmacol"},{"key":"1472_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34696-6","volume":"13","author":"Y Qian","year":"2022","unstructured":"Qian Y, Wang J, Yang L, Liu Y, Wang L, Liu W, et al. Activation and signaling mechanism revealed by GPR119-Gs complex structures. Nat Commun. 2022;13:7033.","journal-title":"Nat Commun"},{"key":"1472_CR84","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bcp.2016.08.018","volume":"119","author":"HA Hassing","year":"2016","unstructured":"Hassing HA, Fares S, Larsen O, Pad H, Hauge M, Jones RM, et al. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. Biochem Pharmacol. 2016;119:66\u201375.","journal-title":"Biochem Pharmacol"},{"key":"1472_CR85","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ardp.200800096","volume":"341","author":"G Swaminath","year":"2008","unstructured":"Swaminath G. Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch Pharmacol. 2008;341:753\u201361.","journal-title":"Arch Pharmacol"},{"key":"1472_CR86","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/TCRM.S1132","volume":"4","author":"MA Ware","year":"2008","unstructured":"Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag. 2008;4:99\u2013107.","journal-title":"Ther Clin Risk Manag"},{"key":"1472_CR87","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1517\/13543770903436505","volume":"19","author":"GA Thakur","year":"2009","unstructured":"Thakur GA, Tichkule R, Bajaj S, Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat. 2009;19:1647\u201373.","journal-title":"Expert Opin Ther Pat"},{"key":"1472_CR88","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000521683","volume":"107","author":"CA Legare","year":"2022","unstructured":"Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. 2022;107:131\u201349.","journal-title":"Pharmacology."},{"key":"1472_CR89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0009-3084(02)00143-3","volume":"121","author":"SL Palmer","year":"2002","unstructured":"Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. Chem Phys Lipids. 2002;121:3\u201319.","journal-title":"Chem Phys Lipids"},{"key":"1472_CR90","doi-asserted-by":"crossref","unstructured":"Thakur GA, Nikas SP, Li C, Makriyannis A. Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol. Cannabinoids 2005:209\u201346.","DOI":"10.1007\/3-540-26573-2_7"},{"key":"1472_CR91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0009-3084(00)00186-9","volume":"108","author":"AD Khanolkar","year":"2000","unstructured":"Khanolkar AD, Palmer SL, Makriyannis A. Molecular probes for the cannabinoid receptors. Chem Phys Lipids. 2000;108:37\u201352.","journal-title":"Chem Phys Lipids"},{"key":"1472_CR92","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/0024-3205(90)90147-J","volume":"47","author":"A Makriyannis","year":"1990","unstructured":"Makriyannis A, Rapaka RS. The molecular basis of cannabinoid activity. Life Sci. 1990;47:2173\u201384.","journal-title":"Life Sci"},{"key":"1472_CR93","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0031-6997(25)06863-2","volume":"38","author":"RK Razdan","year":"1986","unstructured":"Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev. 1986;38:75\u2013149.","journal-title":"Pharmacol Rev"},{"key":"1472_CR94","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"AC Howlett","year":"2002","unstructured":"Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161\u2013202.","journal-title":"Pharmacol Rev"},{"key":"1472_CR95","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0968-0896(02)00649-1","volume":"11","author":"JW Huffman","year":"2003","unstructured":"Huffman JW, Miller JRA, Liddle J, Yu S, Thomas BF, Wiley JL, et al. Structure-activity relationships for 1\u2019,1\u2019-dimethylalkyl-Delta8-tetrahydrocannabinols. Bioorg Med Chem. 2003;11:1397\u2013410.","journal-title":"Bioorg Med Chem"},{"key":"1472_CR96","first-page":"1995","volume":"22","author":"H Edery","year":"1972","unstructured":"Edery H, Grunfeld Y, Porath G, Ben-Zvi Z, Shani A, Mechoulam R. Structure-activity relationships in the tetrahydrocannabinol series. Modifications on the aromatic ring and it the side-chain. Arzneimittelforschung. 1972;22:1995\u20132003.","journal-title":"Arzneimittelforschung"},{"key":"1472_CR97","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/0024-3205(95)00184-8","volume":"56","author":"JW Huffman","year":"1995","unstructured":"Huffman JW, Lainton JA, Dai D, Jordan RD, Duncan SG. Variation of the alkyl side chain in delta 8-THC. Life Sci. 1995;56:2021\u20134.","journal-title":"Life Sci"},{"key":"1472_CR98","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/0024-3205(95)00182-6","volume":"56","author":"MA Tius","year":"1995","unstructured":"Tius MA, Hill WA, Zou XL, Busch-Petersen J, Kawakami JK, Fernandez-Garcia MC, et al. Classical\/non-classical cannabinoid hybrids; stereochemical requirements for the southern hydroxyalkyl chain. Life Sci. 1995;56:2007\u201312.","journal-title":"Life Sci"},{"key":"1472_CR99","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1021\/ja01173a023","volume":"71","author":"R Adams","year":"1949","unstructured":"Adams R, Harfenist M, Loewe S. New analogs of tetrahydrocannabinol. XIX. J Am Chem Soc. 1949;71:1624\u20138.","journal-title":"XIX. J Am Chem Soc"},{"key":"1472_CR100","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/BF01959156","volume":"44","author":"R Mechoulam","year":"1988","unstructured":"Mechoulam R, Feigenbaum JJ, Lander N, Segal M, J\u00e4rbe TU, Hiltunen AJ, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia. 1988;44:762\u20134.","journal-title":"Experientia."},{"key":"1472_CR101","first-page":"15","volume":"79","author":"R Mechoulam","year":"1987","unstructured":"Mechoulam R, Lander N, Srebnik M, Breuer A, Segal M, Feigenbaum JJ, et al. Stereochemical requirements for cannabimimetic activity. NIDA Res Monogr. 1987;79:15\u201330.","journal-title":"NIDA Res Monogr"},{"key":"1472_CR102","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0091-3057(91)90355-6","volume":"40","author":"A Charalambous","year":"1991","unstructured":"Charalambous A, Lin S, Marciniak G, Banijamali A, Friend FL, Compton DR, et al. Pharmacological evaluation of halogenated delta 8-THC analogs. Pharmacol Biochem Behav. 1991;40:509\u201312.","journal-title":"Pharmacol Biochem Behav"},{"key":"1472_CR103","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0091-3057(93)90356-X","volume":"46","author":"BR Martin","year":"1993","unstructured":"Martin BR, Compton DR, Semus SF, Lin S, Marciniak G, Grzybowska J, et al. Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC. Pharmacol Biochem Behav. 1993;46:295\u2013301.","journal-title":"Pharmacol Biochem Behav"},{"key":"1472_CR104","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1208\/aapsj060430","volume":"6","author":"SP Nikas","year":"2004","unstructured":"Nikas SP, Grzybowska J, Papahatjis DP, Charalambous A, Banijamali AR, Chari R, et al. The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model. AAPS J. 2004;6:e30.","journal-title":"AAPS J"},{"key":"1472_CR105","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1021\/jm00094a023","volume":"35","author":"A Charalambous","year":"1992","unstructured":"Charalambous A, Yan G, Houston DB, Howlett AC, Compton DR, Martin BR, et al. 5\u2019-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor. J Med Chem. 1992;35:3076\u20139.","journal-title":"J Med Chem"},{"key":"1472_CR106","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1021\/jm9803875","volume":"41","author":"M Singer","year":"1998","unstructured":"Singer M, Ryan WJ, Saha B, Martin BR, Razdan RK. Potent cyano and carboxamido side-chain analogues of 1\u2019, 1\u2019-dimethyl-delta8-tetrahydrocannabinol. J Med Chem. 1998;41:4400\u20137.","journal-title":"J Med Chem"},{"key":"1472_CR107","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1124\/mol.105.014407","volume":"68","author":"RP Picone","year":"2005","unstructured":"Picone RP, Khanolkar AD, Xu W, Ayotte LA, Thakur GA, Hurst DP, et al. (-)-7\u2019-Isothiocyanato-11-hydroxy-1\u2019,1\u2019-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol. 2005;68:1623\u201335.","journal-title":"Mol Pharmacol"},{"key":"1472_CR108","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nature23272","volume":"547","author":"T Hua","year":"2017","unstructured":"Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, et al. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 2017;547:468\u201371.","journal-title":"Nature."},{"key":"1472_CR109","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1021\/jm058175c","volume":"48","author":"D Lu","year":"2005","unstructured":"Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, et al. Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem. 2005;48:4576\u201385.","journal-title":"J Med Chem"},{"key":"1472_CR110","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1021\/jm960394y","volume":"39","author":"JW Huffman","year":"1996","unstructured":"Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, et al. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem. 1996;39:3875\u20137.","journal-title":"J Med Chem"},{"key":"1472_CR111","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/sj.bjp.0702836","volume":"128","author":"RA Ross","year":"1999","unstructured":"Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK, et al. Structural determinants of the partial agonist-inverse agonist properties of 6\u2019-azidohex-2\u2019-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol. 1999;128:735\u201343.","journal-title":"Br J Pharmacol"},{"key":"1472_CR112","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0022-3565(24)37418-X","volume":"285","author":"G Griffin","year":"1998","unstructured":"Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5\u2019-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther. 1998;285:553\u201360.","journal-title":"J Pharmacol Exp Ther"},{"key":"1472_CR113","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0026-895X(25)13196-9","volume":"33","author":"AC Howlett","year":"1988","unstructured":"Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol. 1988;33:297\u2013302.","journal-title":"Mol Pharmacol"},{"key":"1472_CR114","doi-asserted-by":"publisher","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","volume":"96","author":"L Hanus","year":"1999","unstructured":"Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1472_CR115","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S0026-895X(24)12547-3","volume":"56","author":"ZH Song","year":"1999","unstructured":"Song ZH, Slowey CA, Hurst DP, Reggio PH. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol Pharmacol. 1999;56:834\u201340.","journal-title":"Mol Pharmacol"},{"key":"1472_CR116","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1021\/jm970257g","volume":"41","author":"S Lin","year":"1998","unstructured":"Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41:5353\u201361.","journal-title":"J Med Chem"},{"key":"1472_CR117","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/0024-3205(95)00187-B","volume":"56","author":"IB Adams","year":"1995","unstructured":"Adams IB, Ryan W, Singer M, Razdan RK, Compton DR, Martin BR. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 1995;56:2041\u20138.","journal-title":"Life Sci"},{"key":"1472_CR118","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S0022-3565(25)09592-8","volume":"273","author":"IB Adams","year":"1995","unstructured":"Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, et al. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther. 1995;273:1172\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"1472_CR119","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2174\/156802608783498050","volume":"8","author":"N Jagerovic","year":"2008","unstructured":"Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem. 2008;8:205\u201330.","journal-title":"Curr Top Med Chem"},{"key":"1472_CR120","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1021\/jm980363y","volume":"42","author":"R Lan","year":"1999","unstructured":"Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem. 1999;42:769\u201376.","journal-title":"J Med Chem"},{"key":"1472_CR121","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","volume":"350","author":"M Rinaldi-Carmona","year":"1994","unstructured":"Rinaldi-Carmona M, Barth F, H\u00e9aulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240\u20134.","journal-title":"FEBS Lett"},{"key":"1472_CR122","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"JP Despr\u00e9s","year":"2005","unstructured":"Despr\u00e9s JP, Golay A, Sj\u00f6str\u00f6m L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121\u201334.","journal-title":"N Engl J Med"},{"key":"1472_CR123","first-page":"89","volume":"60","author":"J Ducobu","year":"2005","unstructured":"Ducobu J, Sternon J. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. J Pharm Belg. 2005;60:89\u201391.","journal-title":"J Pharm Belg"},{"key":"1472_CR124","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jacc.2005.12.067","volume":"47","author":"EV Gelfand","year":"2006","unstructured":"Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006;47:1919\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"1472_CR125","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S0022-3565(24)37266-0","volume":"284","author":"M Rinaldi-Carmona","year":"1998","unstructured":"Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998;284:644\u201350.","journal-title":"J Pharmacol Exp Ther"},{"key":"1472_CR126","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","volume":"176","author":"X Li","year":"2019","unstructured":"Li X, Hua T, Vemuri K, Ho J-H, Wu Y, Wu L, et al. Crystal structure of the human cannabinoid receptor CB2. Cell. 2019;176:459\u201367.e13.","journal-title":"Cell."},{"key":"1472_CR127","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/acs.jmedchem.1c01836","volume":"65","author":"MR Iyer","year":"2022","unstructured":"Iyer MR, Cinar R, Wood CM, Zawatsky CN, Coffey NJ, Kim KA, et al. Synthesis, biological evaluation, and molecular modeling studies of 3,4-diarylpyrazoline series of compounds as potent, nonbrain penetrant antagonists of cannabinoid-1 (CB1R) receptor with reduced lipophilicity. J Med Chem. 2022;65:2374\u201387.","journal-title":"J Med Chem"},{"key":"1472_CR128","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1021\/acs.jmedchem.6b01504","volume":"60","author":"MR Iyer","year":"2017","unstructured":"Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, et al. Design, synthesis, and biological evaluation of novel, non-brain-penetrant, hybrid cannabinoid CB1R inverse agonist\/inducible nitric oxide synthase (iNOS) inhibitors for the treatment of liver fibrosis. J Med Chem. 2017;60:1126\u201341.","journal-title":"J Med Chem"},{"key":"1472_CR129","doi-asserted-by":"publisher","first-page":"e92281","DOI":"10.1172\/jci.insight.92281","volume":"2","author":"R Cinar","year":"2017","unstructured":"Cinar R, Gochuico BR, Iyer MR, Jourdan T, Yokoyama T, Park JK, et al. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight. 2017;2:e92281.","journal-title":"JCI Insight"},{"key":"1472_CR130","doi-asserted-by":"publisher","first-page":"107477","DOI":"10.1016\/j.pharmthera.2020.107477","volume":"208","author":"R Cinar","year":"2020","unstructured":"Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB1R antagonists. Pharmacol Ther. 2020;208:107477.","journal-title":"Pharmacol Ther"},{"key":"1472_CR131","doi-asserted-by":"publisher","first-page":"e87336","DOI":"10.1172\/jci.insight.87336","volume":"1","author":"R Cinar","year":"2016","unstructured":"Cinar R, Iyer MR, Liu Z, Cao Z, Jourdan T, Erdelyi K, et al. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight. 2016;1:e87336.","journal-title":"JCI Insight"},{"key":"1472_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54206-0","volume":"15","author":"P Kumari","year":"2024","unstructured":"Kumari P, Dvor\u00e1csk\u00f3 S, Enos MD, Ramesh K, Lim D, Hassan SA, et al. Structural mechanism of CB1R binding to peripheral and biased inverse agonists. Nat Commun. 2024;15:10694.","journal-title":"Nat Commun"},{"key":"1472_CR133","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","volume":"167","author":"T Hua","year":"2016","unstructured":"Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, et al. Crystal structure of the human cannabinoid receptor CB1. Cell. 2016;167:750\u201362.e14.","journal-title":"Cell."},{"key":"1472_CR134","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nature20613","volume":"540","author":"Z Shao","year":"2016","unstructured":"Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J, et al. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 2016;540:602\u20136.","journal-title":"Nature."},{"key":"1472_CR135","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","volume":"176","author":"K Krishna Kumar","year":"2019","unstructured":"Krishna Kumar K, Shalev-Benami M, Robertson MJ, Hu H, Banister SD, Hollingsworth SA, et al. Structure of a signaling cannabinoid receptor 1-G protein complex. Cell. 2019;176:448\u201358.e12.","journal-title":"Cell."},{"key":"1472_CR136","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1016\/j.cell.2023.11.017","volume":"186","author":"YY Liao","year":"2023","unstructured":"Liao YY, Zhang H, Shen Q, Cai C, Ding Y, et al. Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism. Cell. 2023;186:5784\u201397.","journal-title":"Cell."},{"key":"1472_CR137","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/procel\/pwad055","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wu L, Wang T, Liu J, Li F, Jiang L, et al. Cryo-EM structure of cannabinoid receptor CB1-\u03b2-arrestin complex. Protein Cell. 2024;15:230\u20134.","journal-title":"Protein Cell"},{"key":"1472_CR138","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41589-022-01038-y","volume":"18","author":"X Yang","year":"2022","unstructured":"Yang X, Wang X, Xu Z, Wu C, Zhou Y, Wang Y, et al. Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1. Nat Chem Biol. 2022;18:831\u201340.","journal-title":"Nat Chem Biol"},{"key":"1472_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37112-9","volume":"14","author":"X Li","year":"2023","unstructured":"Li X, Chang H, Bouma J, de Paus LV, Mukhopadhyay P, Paloczi J, et al. Structural basis of selective cannabinoid CB2 receptor activation. Nat Commun. 2023;14:1447.","journal-title":"Nat Commun"},{"key":"1472_CR140","doi-asserted-by":"publisher","first-page":"e2401091121","DOI":"10.1073\/pnas.2401091121","volume":"121","author":"X Yang","year":"2024","unstructured":"Yang X, Zhou P, Shen S, Hu Q, Tian C, Xia A, et al. Entropy drives the ligand recognition in G-protein-coupled receptor subtypes. Proc Natl Acad Sci USA. 2024;121:e2401091121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1472_CR141","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1021\/acs.jmedchem.2c01943","volume":"66","author":"J Nan","year":"2023","unstructured":"Nan J, Liu J, Lin G, Zhang S, Xia A, Zhou P, et al. Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one derivatives as a new class of cannabinoid type 2 receptor agonists for the treatment of inflammatory pain. J Med Chem. 2023;66:3460\u201383.","journal-title":"J Med Chem"},{"key":"1472_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.11.014","volume":"128","author":"S Mallipeddi","year":"2017","unstructured":"Mallipeddi S, Janero DR, Zvonok N, Makriyannis A. Functional selectivity at G-protein coupled receptors: advancing cannabinoid receptors as drug targets. Biochem Pharmacol. 2017;128:1\u201311.","journal-title":"Biochem Pharmacol"},{"key":"1472_CR143","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1515\/jbcpp-2015-0096","volume":"27","author":"K Eldeeb","year":"2016","unstructured":"Eldeeb K, Leone-Kabler S, Howlett AC. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi\/o function. J Basic Clin Physiol Pharmacol. 2016;27:311\u201322.","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"1472_CR144","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1124\/mol.116.104539","volume":"90","author":"C Nogueras-Ortiz","year":"2016","unstructured":"Nogueras-Ortiz C, Yudowski GA. The multiple waves of cannabinoid 1 receptor signaling. Mol Pharmacol. 2016;90:620\u20136.","journal-title":"Mol Pharmacol"},{"key":"1472_CR145","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1517\/13543784.2014.918603","volume":"23","author":"MP Davis","year":"2014","unstructured":"Davis MP. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert Opin Investig Drugs. 2014;23:1123\u201340.","journal-title":"Expert Opin Investig Drugs"},{"key":"1472_CR146","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","volume":"97","author":"JL Wiley","year":"2014","unstructured":"Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 2014;97:55\u201363.","journal-title":"Life Sci"},{"key":"1472_CR147","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.tips.2020.06.010","volume":"41","author":"X Li","year":"2020","unstructured":"Li X, Shen L, Hua T, Liu ZJ. Structural and functional insights into cannabinoid receptors. Trends Pharmacol Sci. 2020;41:665\u201377.","journal-title":"Trends Pharmacol Sci"},{"key":"1472_CR148","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2174\/1871527316666170413101839","volume":"16","author":"G Martinotti","year":"2017","unstructured":"Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O. Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets. 2017;16:567\u201375.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1472_CR149","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/phar.1187","volume":"33","author":"LM Borgelt","year":"2013","unstructured":"Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33:195\u2013209.","journal-title":"Pharmacotherapy."},{"key":"1472_CR150","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/sj.bjp.0702228","volume":"125","author":"DM Hutcheson","year":"1998","unstructured":"Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br J Pharmacol. 1998;125:1567\u201377.","journal-title":"Br J Pharmacol"},{"key":"1472_CR151","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/13543776.2019.1597851","volume":"29","author":"G Amato","year":"2019","unstructured":"Amato G, Khan NS, Maitra R. A patent update on cannabinoid receptor 1 antagonists (2015-2018). Expert Opin Ther Pat. 2019;29:261\u20139.","journal-title":"Expert Opin Ther Pat"},{"key":"1472_CR152","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/j.ddtec.2012.08.004","volume":"10","author":"ZG Gao","year":"2013","unstructured":"Gao ZG, Jacobson KA. Allosteric modulation and functional selectivity of G protein-coupled receptors. Drug Discov Today Technol. 2013;10:e237\u201343.","journal-title":"Drug Discov Today Technol"},{"key":"1472_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","volume":"47","author":"LT May","year":"2007","unstructured":"May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2007;47:1\u201351.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1472_CR154","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s43556-023-00156-w","volume":"4","author":"L Cheng","year":"2023","unstructured":"Cheng L, Xia F, Li Z, Shen C, Yang Z, Hou H, et al. Structure, function and drug discovery of GPCR signaling. Mol Biomed. 2023;4:46.","journal-title":"Mol Biomed"},{"key":"1472_CR155","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","volume":"42","author":"LM Slosky","year":"2021","unstructured":"Slosky LM, Caron MG, Barak LS. Biased allosteric modulators: new frontiers in GPCR drug discovery. Trends Pharmacol Sci. 2021;42:283\u201399.","journal-title":"Trends Pharmacol Sci"},{"key":"1472_CR156","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/cells12071046","volume":"12","author":"KM Reid","year":"2023","unstructured":"Reid KM, Steel D, Nair S, Bhate S, Biassoni L, Sudhakar S, et al. Loss-of-function variants in DRD1 in infantile Parkinsonism-Dystonia. Cells. 2023;12:1046.","journal-title":"Cells."},{"key":"1472_CR157","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1021\/acs.jmedchem.8b00875","volume":"62","author":"EA Wold","year":"2019","unstructured":"Wold EA, Chen J, Cunningham KA, Zhou J. Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts. J Med Chem. 2019;62:88\u2013127.","journal-title":"J Med Chem"},{"key":"1472_CR158","doi-asserted-by":"publisher","first-page":"19478","DOI":"10.1074\/jbc.R115.662759","volume":"290","author":"PR Gentry","year":"2015","unstructured":"Gentry PR, Sexton PM, Christopoulos A. Novel allosteric modulators of G protein-coupled receptors. J Biol Chem. 2015;290:19478\u201388.","journal-title":"J Biol Chem"},{"key":"1472_CR159","doi-asserted-by":"publisher","first-page":"21134","DOI":"10.1073\/pnas.1202906109","volume":"109","author":"FA Pamplona","year":"2012","unstructured":"Pamplona FA, Ferreira J, Menezes de Lima O, Duarte FS, Bento AF, Forner S, et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci USA. 2012;109:21134\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1472_CR160","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1038\/npp.2015.148","volume":"40","author":"BM Ignatowska-Jankowska","year":"2015","unstructured":"Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, et al. A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology. 2015;40:2948\u201359.","journal-title":"Neuropsychopharmacology."},{"key":"1472_CR161","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1021\/acschemneuro.6b00310","volume":"8","author":"RB Laprairie","year":"2017","unstructured":"Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, et al. Enantiospecific allosteric modulation of cannabinoid 1 receptor. ACS Chem Neurosci. 2017;8:1188\u2013203.","journal-title":"ACS Chem Neurosci"},{"key":"1472_CR162","doi-asserted-by":"crossref","unstructured":"Saleh N, Hucke O, Kramer G, Schmidt E, Montel F, Lipinski R, et al. Multiple binding sites contribute to the mechanism of mixed agonistic and positive allosteric modulators of the cannabinoid CB1 receptor. Angew Chem Int Ed. 2018;57:2580\u20135.","DOI":"10.1002\/anie.201708764"},{"key":"1472_CR163","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1021\/acs.jmedchem.1c00040","volume":"64","author":"S Garai","year":"2021","unstructured":"Garai S, Leo LM, Szczesniak A-M, Hurst DP, Schaffer PC, Zagzoog A, et al. Discovery of a biased allosteric modulator for cannabinoid 1 receptor: preclinical anti-glaucoma efficacy. J Med Chem. 2021;64:8104\u201326.","journal-title":"J Med Chem"},{"key":"1472_CR164","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1124\/mol.105.016162","volume":"68","author":"MR Price","year":"2005","unstructured":"Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005;68:1484\u201395.","journal-title":"Mol Pharmacol"},{"key":"1472_CR165","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/mol.112.080879","volume":"83","author":"GL Baillie","year":"2013","unstructured":"Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, et al. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol. 2013;83:322\u201338.","journal-title":"Mol Pharmacol"},{"key":"1472_CR166","doi-asserted-by":"publisher","first-page":"12070","DOI":"10.1074\/jbc.M111.316463","volume":"287","author":"KH Ahn","year":"2012","unstructured":"Ahn KH, Mahmoud MM, Kendall DA. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1\/2 kinase activation. J Biol Chem. 2012;287:12070\u201382.","journal-title":"J Biol Chem"},{"key":"1472_CR167","doi-asserted-by":"publisher","first-page":"e00069","DOI":"10.1002\/prp2.69","volume":"2","author":"Y Ding","year":"2014","unstructured":"Ding Y, Qiu Y, Jing L, Thorn DA, Zhang Y, Li JX. Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats. Pharmacol Res Perspect. 2014;2:e00069.","journal-title":"Pharmacol Res Perspect"},{"key":"1472_CR168","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/FBP.0000000000000027","volume":"25","author":"TF Gamage","year":"2014","unstructured":"Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, et al. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol. 2014;25:182\u20135.","journal-title":"Behav Pharmacol"},{"key":"1472_CR169","doi-asserted-by":"publisher","first-page":"36944","DOI":"10.1074\/jbc.M112.382481","volume":"287","author":"M Bauer","year":"2012","unstructured":"Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, et al. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem. 2012;287:36944\u201367.","journal-title":"J Biol Chem"},{"key":"1472_CR170","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1126\/science.1243985","volume":"343","author":"M Vall\u00e9e","year":"2014","unstructured":"Vall\u00e9e M, Vitiello S, Bellocchio L, H\u00e9bert-Chatelain E, Monlezun S, Martin-Garcia E, et al. Pregnenolone can protect the brain from cannabis intoxication. Science. 2014;343:94\u20138.","journal-title":"Science."},{"key":"1472_CR171","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172:4790\u2013805.","journal-title":"Br J Pharmacol"},{"key":"1472_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09808-8","volume":"7","author":"V Petrucci","year":"2017","unstructured":"Petrucci V, Chicca A, Glasmacher S, Paloczi J, Cao Z, Pacher P, et al. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. Sci Rep. 2017;7:9560.","journal-title":"Sci Rep"},{"key":"1472_CR173","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1021\/acs.jmedchem.8b00368","volume":"62","author":"F Gado","year":"2019","unstructured":"Gado F, Di Cesare Mannelli L, Lucarini E, Bertini S, Cappelli E, Digiacomo M, et al. Identification of the first synthetic allosteric modulator of the CB2 receptors and evidence of its efficacy for neuropathic pain relief. J Med Chem. 2019;62:276\u201387.","journal-title":"J Med Chem"},{"key":"1472_CR174","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41589-019-0387-2","volume":"15","author":"Z Shao","year":"2019","unstructured":"Shao Z, Yan W, Chapman K, Ramesh K, Ferrell AJ, Yin J, et al. Structure of an allosteric modulator bound to the CB1 cannabinoid receptor. Nat Chem Biol. 2019;15:1199\u2013205.","journal-title":"Nat Chem Biol"},{"key":"1472_CR175","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/PL00000643","volume":"57","author":"K Burger","year":"2000","unstructured":"Burger K, Gimpl G, Fahrenholz F. Regulation of receptor function by cholesterol. Cell Mol Life Sci. 2000;57:1577\u201392.","journal-title":"Cell Mol Life Sci"},{"key":"1472_CR176","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1126\/science.290.5497.1721","volume":"290","author":"K Simons","year":"2000","unstructured":"Simons K, Ikonen E. How cells handle cholesterol. Science. 2000;290:1721\u20136.","journal-title":"Science."},{"key":"1472_CR177","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/ijms22041953","volume":"22","author":"J Jakub\u00edk","year":"2021","unstructured":"Jakub\u00edk J, El-Fakahany EE. Allosteric modulation of GPCRs of class A by cholesterol. Int J Mol Sci. 2021;22:1953.","journal-title":"Int J Mol Sci"},{"key":"1472_CR178","doi-asserted-by":"publisher","first-page":"16320","DOI":"10.1021\/jacs.1c06847","volume":"143","author":"X Wang","year":"2021","unstructured":"Wang X, Liu D, Shen L, Li F, Li Y, Yang L, et al. A genetically encoded F-19 NMR probe reveals the allosteric modulation mechanism of cannabinoid receptor 1. J Am Chem Soc. 2021;143:16320\u20135.","journal-title":"J Am Chem Soc"},{"key":"1472_CR179","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/mol.106.028258","volume":"71","author":"CE Groer","year":"2007","unstructured":"Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, et al. An opioid agonist that does not induce mu-opioid receptor\u2013arrestin interactions or receptor internalization. Mol Pharmacol. 2007;71:549\u201357.","journal-title":"Mol Pharmacol"},{"key":"1472_CR180","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.drugalcdep.2011.10.026","volume":"121","author":"K Lamb","year":"2012","unstructured":"Lamb K, Tidgewell K, Simpson DS, Bohn LM, Prisinzano TE. Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend. 2012;121:181\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"1472_CR181","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.cell.2020.04.053","volume":"181","author":"LM Slosky","year":"2020","unstructured":"Slosky LM, Bai Y, Toth K, Ray C, Rochelle LK, Badea A, et al. \u03b2-arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors. Cell. 2020;181:1364\u201379.e14.","journal-title":"Cell."},{"key":"1472_CR182","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/FBP.0b013e328308f1e6","volume":"19","author":"CS Breivogel","year":"2008","unstructured":"Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK. Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-\/- mice. Behav Pharmacol. 2008;19:298\u2013307.","journal-title":"Behav Pharmacol"},{"key":"1472_CR183","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.biopsych.2011.11.027","volume":"71","author":"PT Nguyen","year":"2012","unstructured":"Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ. \u03b2-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry. 2012;71:714\u201324.","journal-title":"Biol Psychiatry"},{"key":"1472_CR184","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41591-023-02381-w","volume":"29","author":"M Haney","year":"2023","unstructured":"Haney M, Vall\u00e9e M, Fabre S, Collins Reed S, Zanese M, Campistron G, et al. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med. 2023;29:1487\u201399.","journal-title":"Nat Med"},{"key":"1472_CR185","doi-asserted-by":"publisher","first-page":"e2321532121","DOI":"10.1073\/pnas.2321532121","volume":"121","author":"S Shen","year":"2024","unstructured":"Shen S, Wu C, Lin G, Yang X, Zhou Y, Zhao C, et al. Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1. Proc Natl Acad Sci USA. 2024;121:e2321532121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1472_CR186","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2174\/0929867306666220401143808","volume":"6","author":"F Barth","year":"1999","unstructured":"Barth F, Rinaldi-Carmona M. The development of cannabinoid antagonists. Curr Med Chem. 1999;6:745\u201355.","journal-title":"Curr Med Chem"},{"key":"1472_CR187","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","volume":"19","author":"T Nguyen","year":"2019","unstructured":"Nguyen T, Thomas BF, Zhang Y. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development. Curr Top Med Chem. 2019;19:1418\u201335.","journal-title":"Curr Top Med Chem"},{"key":"1472_CR188","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1002\/oby.23902","volume":"31","author":"M Morningstar","year":"2023","unstructured":"Morningstar M, Kolodziej A, Ferreira S, Blumen T, Brake R, Cohen Y. Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model. Obesity. 2023;31:2676\u201388.","journal-title":"Obesity."},{"key":"1472_CR189","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/dom.15353","volume":"26","author":"GD Crater","year":"2024","unstructured":"Crater GD, Lalonde K, Ravenelle F, Harvey M, Despr\u00e9s JP. Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study. Diabetes Obes Metab. 2024;26:642\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1472_CR190","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.tips.2022.06.010","volume":"43","author":"ZM Whiting","year":"2022","unstructured":"Whiting ZM, Yin J, de la Harpe SM, Vernall AJ, Grimsey NL. Developing the cannabinoid receptor 2 (CB2) pharmacopoeia: past, present, and future. Trends Pharmacol Sci. 2022;43:754\u201371.","journal-title":"Trends Pharmacol Sci"},{"key":"1472_CR191","doi-asserted-by":"publisher","first-page":"e03159","DOI":"10.7554\/eLife.03159","volume":"3","author":"AB Roland","year":"2014","unstructured":"Roland AB, Ricobaraza A, Carrel D, Jordan BM, Rico F, Simon A, et al. Cannabinoid-induced actomyosin contractility shapes neuronal morphology and growth. eLife. 2014;3:e03159.","journal-title":"eLife"},{"key":"1472_CR192","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.phrs.2017.08.008","volume":"125","author":"BM Ford","year":"2017","unstructured":"Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, et al. Characterization of structurally novel G protein biased CB1 agonists: implications for drug development. Pharmacol Res. 2017;125:161\u201377.","journal-title":"Pharmacol Res"},{"key":"1472_CR193","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5551\/jat.33928","volume":"23","author":"M Shinohara","year":"2016","unstructured":"Shinohara M, Serhan CN. Novel endogenous proresolving molecules: essential fatty acid-derived and gaseous mediators in the resolution of inflammation. J Atheroscler Thromb. 2016;23:655\u201364.","journal-title":"J Atheroscler Thromb"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01472-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01472-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:03:35Z","timestamp":1747911815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01472-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":193,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1038\/s41401-024-01472-9","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}